The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease
Abstract
O P T I M I S M A B O U T therapeutic interventions in Alzheimer disease is based largely on a growing confidence that we understand theunderlyingpathobiologyof the illness.Breakthroughs ingenetics ledtotheidentificationof3early-onset Alzheimer disease autosomal dominant genes, each of which affects the metabolism of the small -amyloid (A ) peptide. This peptide is the core component of senile plaques, 1 of the 2 major histopathological hallmarksof thedisease.Biochemical and molecular analyses ultimately led to the identification of the and -secretases, enzymes important in generating A , and innovative approachesaimedatclearingA , including immunotherapy, have emerged. Giventhis intensive investigationinto the pathology of A , and the emergence of pharmacological targets directly relatedtoA metabolism,hope was strong that effectivewaysofhaltingor reversing thediseasewerenear at hand. However, a series of disappointing results from large clinical trials have ensued. Perhaps it would havebeenunrealistictoexpectthefirst generation of pharmacologic agents to be blockbusters, but even modest signals of clinical efficacy have been elusive.Thefirstactive immunization program was halted because of meningealencephalitis inasmallpercentage of the patients, but long followup of patients who were in the trial to autopsy showed no clear change in clinical course despite dramatic clearance of amyloid. In a more recent failure, the development of a -secretase inhibitor was halted because of systemic adverse effects, as wellasbecausepatients’cognitionnot only did not improve, but apparently got worse. Whatwentwrongwiththeserecent clinical trials? Is the “A hypothesis” in need of revision? The strong case from genetics and the fact that all patientswithAlzheimerdiseasehave innumerable amyloid plaques in their brains and elevated levels of synaptotoxic soluble amyloid still make the strongestpossiblecasethatA isacritical factor in the disease. However, it hasbeenrecognizedforyearsthatthere arepoorclinicalpathological correlations between plaques and the extent of cognitive impairment in patients with Alzheimer disease, whereas the otherhistologic featuresofAlzheimer disease—neuronal loss, synaptic loss, and neurofibrillary tangles—tend to match up much better with clinical symptoms. I propose in this commentary that the amyloid hypothesis needs to be reformulated to posit a 2-stageprocess inwhichamyloid initiates a cascade of pathophysiologic consequences,which in turnbecome increasingly independentof the initiatingamyloid.Thisrevisedhypothesis wouldexplain theapparent lackofefficacyof targetingA after thedisease isestablishedandsupports thesearch for therapies aimed at downstream events thatare theproximatecauseof neurodegeneration and dementia. One of the pillars of this new formulationis theobservationthat innumerableindividualshaveaccumulated amyloid plaques in their brains but donothavedementia. Asmanyas 30% of cognitively normal individuals in their 70s have amyloid plaques by positron emission tomography scans. These data concur with previous autopsy studies that had highlighted the possibility that amyloid plaques could accumulate even in “normal” individuals. Moreover, the numberofamyloidplaques thataccumulate in the brain appears to reach a near maximal level by the time patients have clinically apparent symptomsofcognitiveimpairment. Inan autopsy-based cross-sectional study, we foundthat amyloiddepositionaccumulated prior to the development of cognitive impairment, and thereafter, the amount of amyloid in the brain was similar across a wide range ofclinical severity, remainingatanalmostflatplateau.Bycontrast,atrophy, neuronal loss,synaptic loss,andnumberof tangles increasewithseverityof illness (Figure 1). The first phase of the disease, in which we now suggest that soluble oligomeric and fibrillar A accumulates, leads to local disruptionoftheneuropil, lossofdendritic spines, remodeling of neurites, and inflammatory responses. The second phase would consist of the (further)developmentoftangles,neuronal loss, synaptic loss, and glial responses in limbicandassociationcortices, and ultimately throughout the corticalmantle,withneurodegeneration ultimately leading to end-stage organ failure. What would happen if the second phase of the disease proceeds somewhat independently of A ? Dementia in Alzheimer disease would then be envisioned to be similar to the symptoms that a patient who has had heart attacks may display due to congestiveheartfailure.Forthesepatients, lowering their cholesterol level for a fewmonthsorayearwillnot improve their performance on the treadmill. Therapeutic strategies may be necessary to improve the symptoms of organfailureotherthanprimaryprevention strategies aimed at lowering the riskofheart attacks.Medicinehas innumerableexamplesofconditionsthat evolve over time and in which the ultimate cause of disability and illness Author Affiliation: Department of Neurology, Massachusetts General Hospit
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Self-citationDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Self-citationHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer’s Disease
Busche, M. A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K.-H., Haass, C., Staufenbiel, M., Konnerth, A., & Garaschuk, O. (2008) · Science · doi:10.1126/science.1162844 · Cited by 1,125
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Self-citationZempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Self-citationKuchibhotla, K. V., Goldman, S. T., Lattarulo, C. R., Wu, H.-Y., Hyman, B. T., & Bacskai, B. J. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.008 · Cited by 614
Self-citationCaspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease
D'Amelio, M., Cavallucci, V., Middei, S., Marchetti, C., Pacioni, S., Ferri, A., Diamantini, A., De Zio, D., Carrara, P., Battistini, L., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2709 · Cited by 572
Cited by
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Self-citationThe Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Self-citation(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589
Self-citationTesting the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Smoking and increased Alzheimer's disease risk: A review of potential mechanisms
Durazzo, T. C., Mattsson, N., Weiner, M. W., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.009 · Cited by 451
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 441
Brain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406
La Joie, R., Perrotin, A., Barré, L., Hommet, C., Mézenge, F., Ibazizene, M., Camus, V., Abbas, A., Landeau, B., Guilloteau, D., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2170-12.2012 · Cited by 374
“These findings are in line with the idea that, at symptomatic stages of the disease, A does not play a prominent role in ongoing neurodegeneration (Hyman, 2011).”
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Amariglio, R. E., Rentz, D. M., Johnson, K. A., & Sperling, R. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2031 · Cited by 328
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Alzheimer's disease: synapses gone cold
Koffie, R. M., Hyman, B. T., & Spires-Jones, T. L. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-63 · Cited by 308
Self-citationRodriguez-Vieitez, E., Saint-Aubert, L., Carter, S. F., Almkvist, O., Farid, K., Schöll, M., Chiotis, K., Thordardottir, S., Graff, C., Wall, A., et al. (2016) · Brain · doi:10.1093/brain/awv404 · Cited by 300
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291
The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals
Sperling, R. A., Mormino, E. C., Schultz, A. P., Betensky, R. A., Papp, K. V., Amariglio, R. E., Hanseeuw, B. J., Buckley, R., Chhatwal, J., Hedden, T., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25395 · Cited by 286
“However, it is possible that anti-Aβ monotherapy will have more limited efficacy once substantial tau pathology is present, especially if there is an uncoupling of these pathophysiological processes as the disease progresses.(47) Given the association between Aβ and tau, and the observation that elevated levels of neo…”
BackgroundJacobs, H. I. L., Hedden, T., Schultz, A. P., Sepulcre, J., Perea, R. D., Amariglio, R. E., Papp, K. V., Rentz, D. M., Sperling, R. A., & Johnson, K. A. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0070-z · Cited by 270
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Soluble forms of tau are toxic in Alzheimer's disease
Kopeikina, K., Hyman, B., & Spires-Jones, T. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0032-y · Cited by 232
Self-citationLifespan brain activity, β-amyloid, and Alzheimer's disease
Jagust, W. J., & Mormino, E. C. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.09.004 · Cited by 221
“One major challenge to the amyloid hypothesis is the lack of a relationship between Aβ and cognitive function (plaques, for example, are seen in cognitively normal individuals) but these findings can be reconciled through the observation that Aβ initiates downstream functional and structural changes that are more clos…”
Higher Rates of Decline for Women and Apolipoprotein E ε4 Carriers
Holland, D., Desikan, R. S., Dale, A. M., & McEvoy, L. K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3601 · Cited by 219
Amlien, I. K., & Fjell, A. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.017 · Cited by 219
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Brain injury biomarkers are not dependent on β‐amyloid in normal elderly
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23816 · Cited by 183
Pickett, E. K., Herrmann, A. G., McQueen, J., Abt, K., Dando, O., Tulloch, J., Jain, P., Dunnett, S., Sohrabi, S., Fjeldstad, M. P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.044 · Cited by 179
Indicators of amyloid burden in a population-based study of cognitively normal elderly
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163
Spines, plasticity, and cognition in Alzheimer's model mice
Spires-Jones, T., & Knafo, S. (2012) · Neural Plasticity · doi:10.1155/2012/319836 · Cited by 133
Huang, M., Hu, M., Song, Q., Song, H., Huang, J., Gu, X., Wang, X., Chen, J., Kang, T., Feng, X., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b03124 · Cited by 127
(2012) · doi:10.1038/nrneurol.2012.118 · Cited by 122
Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119
“This second stage is hypothesized to progress independently of the amyloid burden [31,33,34].”
Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition
Leonenko, G., Shoai, M., Bellou, E., Sims, R., Williams, J., Hardy, J., Escott‐Price, V., & Initiative, T. A. D. N. (2019) · Annals of Neurology · doi:10.1002/ana.25530 · Cited by 114
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Innate immune system and inflammation in Alzheimer’s disease: From pathogenesis to treatment
Serpente, M., Bonsi, R., Scarpini, E., & Galimberti, D. (2014) · Neuroimmunomodulation · doi:10.1159/000356529 · Cited by 87
Petrov, A. M., Lam, M., Mast, N., Moon, J., Li, Y., Maxfield, E., & Pikuleva, I. A. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00737-0 · Cited by 86
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
“Intervention at the dementia stage therefore could well be too late if amyloid is no longer driving the disease process.(68) Tau pathology is primarily intracellular and so would seem to be a less viable immunotherapy target, although passive immunization strategies in mouse models have shown encouraging effects in li…”
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
“But this will remain an area of active research in coming years, particularly with the advent of amyloid lowering therapies which might be most eff ective if initiated in the presymptomatic disease stage [34].”
BackgroundMarutle, A., Gillberg, P.-G., Bergfors, A., Yu, W., Ni, R., Nennesmo, I., Voytenko, L., & Nordberg, A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-90 · Cited by 70
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.182 · Cited by 68
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels
Steward, A., Biel, D., Dewenter, A., Roemer, S., Wagner, F., Dehsarvi, A., Rathore, S., Otero Svaldi, D., Higgins, I., Brendel, M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4038 · Cited by 67
Neurogranin as a predictor of memory and executive function decline in MCI patients
Headley, A., De Leon-Benedetti, A., Dong, C., Levin, B., Loewenstein, D., Camargo, C., Rundek, T., Zetterberg, H., Blennow, K., Wright, C. B., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005057 · Cited by 62
A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease
Sepulveda-Falla, D., Chavez-Gutierrez, L., Portelius, E., Vélez, J. I., Dujardin, S., Barrera-Ocampo, A., Dinkel, F., Hagel, C., Puig, B., Mastronardi, C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02249-0 · Cited by 54
Self-citationClinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Andrade-Talavera, Y., & Rodríguez-Moreno, A. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.696476 · Cited by 39
The Role of Glial Cells and Synapse Loss in Mouse Models of Alzheimer’s Disease
Ziegler-Waldkirch, S., & Meyer-Luehmann, M. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00473 · Cited by 21
Integrating Transcriptomics, Genomics, and Imaging in Alzheimer's Disease: A Federated Model
Wu, J., Chen, Y., Wang, P., Caselli, R. J., Thompson, P. M., Wang, J., & Wang, Y. (2022) · Frontiers in Radiology · doi:10.3389/fradi.2021.777030 · Cited by 17
Metadata
- Authors
- Hyman, B. T.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2011-08-01
- Volume
- 68
- Issue
- 8
- Pages
- 1062
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2110424796
- Cited by
- 197
- References
- 16
- FWCI
- 13.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.